X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5294) 5294
Publication (1180) 1180
Book Review (102) 102
Book Chapter (52) 52
Book / eBook (21) 21
Conference Proceeding (19) 19
Newsletter (13) 13
Magazine Article (5) 5
Reference (3) 3
Data Set (2) 2
Dissertation (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3254) 3254
index medicus (3173) 3173
humans (2301) 2301
male (1898) 1898
pharmacology & pharmacy (1847) 1847
neurosciences (1655) 1655
cannabinoids (1561) 1561
rats (1313) 1313
mice (1240) 1240
endocannabinoids (1136) 1136
endocannabinoid system (1101) 1101
anandamide (784) 784
receptor, cannabinoid, cb1 - antagonists & inhibitors (756) 756
receptor, cannabinoid, cb1 - metabolism (756) 756
psychiatry (748) 748
pyrazoles - pharmacology (734) 734
piperidines - pharmacology (719) 719
female (697) 697
lipids (662) 662
brain (636) 636
cannabinoid (608) 608
cannabinoids - pharmacology (608) 608
disease models, animal (578) 578
cannabinoid receptors (576) 576
dose-response relationship, drug (574) 574
marijuana (574) 574
article (554) 554
pharmacology (536) 536
rodents (532) 532
cannabinoid receptor (530) 530
activation (493) 493
rats, sprague-dawley (492) 492
analysis (490) 490
cannabinoid cb1 receptors (486) 486
cannabis (485) 485
receptors (476) 476
pain (470) 470
acid amide hydrolase (460) 460
cannabinoids - therapeutic use (450) 450
inflammation (442) 442
rats, wistar (432) 432
nervous system (430) 430
research (426) 426
mice, inbred c57bl (424) 424
rimonabant (421) 421
receptor, cannabinoid, cb2 - metabolism (414) 414
biomedicine (410) 410
physiological aspects (392) 392
clinical neurology (387) 387
health aspects (383) 383
cb1 receptor (377) 377
biochemistry & molecular biology (372) 372
receptor, cannabinoid, cb1 - agonists (371) 371
expression (366) 366
pyrazoles - therapeutic use (365) 365
neurology (364) 364
obesity (364) 364
piperidines - therapeutic use (363) 363
arachidonic acids - pharmacology (358) 358
ligands (354) 354
endocannabinoids - metabolism (348) 348
pharmacology/toxicology (347) 347
cb1 (342) 342
cell biology (336) 336
neurons (329) 329
care and treatment (328) 328
cannabinoid receptor modulators - metabolism (325) 325
morpholines - pharmacology (312) 312
inhibition (308) 308
receptor (308) 308
cb1 receptors (303) 303
cannabidiol (298) 298
medicine (297) 297
naphthalenes - pharmacology (293) 293
receptors, cannabinoid - metabolism (290) 290
dronabinol - pharmacology (284) 284
rat (284) 284
receptor, cannabinoid, cb2 - agonists (284) 284
endocannabinoid (281) 281
fatty acids (280) 280
adult (279) 279
brain - metabolism (278) 278
enzymes (278) 278
signal transduction (273) 273
anxiety (268) 268
obesity - drug therapy (267) 267
mice, knockout (264) 264
brain - drug effects (263) 263
proteins (262) 262
neuropathic pain (261) 261
tetrahydrocannabinol (261) 261
arachidonic acids - metabolism (259) 259
cannabinoid cb2 receptors (255) 255
receptor, cannabinoid, cb1 - physiology (254) 254
endogenous cannabinoids (248) 248
receptor, cannabinoid, cb1 - genetics (247) 247
multidisciplinary sciences (242) 242
review (242) 242
research article (239) 239
in-vivo (237) 237
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5290) 5290
German (30) 30
French (21) 21
Japanese (7) 7
Spanish (7) 7
Italian (5) 5
Portuguese (4) 4
Czech (3) 3
Dutch (3) 3
Hungarian (3) 3
Russian (3) 3
Chinese (2) 2
Norwegian (2) 2
Polish (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 10/2012, Volume 63, Issue 5, pp. 905 - 915
Mu-opioid and CB1-cannabinoid agonists produce analgesia; however, adverse effects limit use of drugs in both classes. Additive or synergistic effects... 
Analgesia | Morphine | Marijuana | G-protein | Adenylyl cyclase | CB1 receptors | AGONIST MORPHINE | ACTIVATION | PROTEIN-KINASE | CB1 CANNABINOID RECEPTOR | SYNERGISTIC INTERACTIONS | NEUROSCIENCES | INHIBITION | KAPPA | FULL AGONIST | ADENYLYL-CYCLASE | PHARMACOLOGY & PHARMACY | RAT-BRAIN | Pyrazoles - therapeutic use | Receptor, Cannabinoid, CB2 - agonists | Humans | Analgesics, Opioid - pharmacology | Receptors, Opioid, mu - agonists | Piperidines - pharmacology | Cannabinoid Receptor Agonists - therapeutic use | Recombinant Proteins - antagonists & inhibitors | Piperidines - metabolism | Receptors, Opioid, mu - metabolism | Morpholines - metabolism | Analgesics, Non-Narcotic - metabolism | Drug Inverse Agonism | Mice | Analgesics, Opioid - metabolism | Kinetics | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Analgesics, Opioid - antagonists & inhibitors | Cannabinoid Receptor Agonists - metabolism | Cricetulus | Analgesics, Non-Narcotic - pharmacology | Cannabinoid Receptor Agonists - pharmacology | Receptor, Cannabinoid, CB2 - genetics | Analgesics, Opioid - adverse effects | Narcotic Antagonists - metabolism | Receptor, Cannabinoid, CB1 - agonists | Analgesics, Non-Narcotic - adverse effects | Cannabinoid Receptor Agonists - adverse effects | Morpholines - adverse effects | CHO Cells | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Binding, Competitive | Recombinant Proteins - metabolism | Cricetinae | Morpholines - pharmacology | Narcotic Antagonists - adverse effects | Recombinant Proteins - agonists | Analgesics, Non-Narcotic - therapeutic use | Pyrazoles - metabolism | Mice, Inbred Strains | Receptors, Opioid, mu - antagonists & inhibitors | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Narcotic Antagonists - therapeutic use | Piperidines - therapeutic use | Narcotic Antagonists - pharmacology | Piperidines - adverse effects | Receptors, Opioid, mu - genetics | Index Medicus | Drugs | Pain perception | Opioid receptors | Cyclic AMP | Opioid receptors (type mu) | Antagonists | Cannabinoid CB1 receptors | Guanine nucleotide-binding protein | Antagonism | Cell activation | Side effects | Inverse agonists | CB1 Receptors | Adenylyl Cyclase
Journal Article
Neuropharmacology, ISSN 0028-3908, 09/2012, Volume 63, Issue 4, pp. 653 - 666
Cannabinoids have been shown to exert neuroprotective effects in a plethora of neurodegenerative conditions. Over the past decade, some studies demonstrate... 
Neuroinflammation | CB2 | CB1 | WIN55212-2 | PPAR-γ | Beta-amyloid | NITRIC-OXIDE SYNTHASE | ALZHEIMERS-DISEASE | NEUROSCIENCES | PPAR-gamma | CELL-DEATH | CASPASE-3 ACTIVATION | CORTICAL-NEURONS | SIGNALING PATHWAY | DNA FRAGMENTATION | IN-VIVO | PHARMACOLOGY & PHARMACY | INFLAMMATORY RESPONSE | NF-KAPPA-B | Receptor, Cannabinoid, CB2 - agonists | Neuroglia - pathology | Injections, Intraventricular | Male | PPAR gamma - metabolism | Alzheimer Disease - pathology | Cannabinoid Receptor Agonists - therapeutic use | Neuroglia - immunology | Nootropic Agents - antagonists & inhibitors | Cannabinoid Receptor Antagonists - pharmacology | Neurons - metabolism | Alzheimer Disease - immunology | Morpholines - therapeutic use | Receptors, Cannabinoid - chemistry | Disease Models, Animal | Benzoxazines - administration & dosage | Nerve Tissue Proteins - agonists | Alzheimer Disease - drug therapy | Rats | Hippocampus - pathology | Random Allocation | PPAR gamma - antagonists & inhibitors | Signal Transduction - drug effects | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Naphthalenes - therapeutic use | Neurons - pathology | Rats, Wistar | Hippocampus - drug effects | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | Cannabinoid Receptor Agonists - chemistry | Neuroglia - drug effects | Receptors, Cannabinoid - metabolism | Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors | Receptor, Cannabinoid, CB1 - agonists | Morpholines - antagonists & inhibitors | Benzoxazines - antagonists & inhibitors | Neurons - drug effects | Nerve Tissue Proteins - antagonists & inhibitors | Hippocampus - immunology | Morpholines - administration & dosage | Neurons - immunology | Nootropic Agents - therapeutic use | Cannabinoid Receptor Agonists - administration & dosage | Benzoxazines - therapeutic use | Nerve Tissue Proteins - metabolism | Hippocampus - metabolism | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Nootropic Agents - administration & dosage | Naphthalenes - administration & dosage | Alzheimer Disease - metabolism | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | PPAR gamma - agonists | Neuroglia - metabolism | Naphthalenes - antagonists & inhibitors
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 06/2013, Volume 169, Issue 4, pp. 808 - 819
Background and purpose JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL), the enzyme that preferentially catabolizes the endocannabinoid... 
monoacylglycerol lipase | endocannabinoid | NF‐κB | TNF‐α | 2‐AG | brain | JZL184 | IL‐6 | IL‐1β | frontal cortex | IL‐10 | cytokines | plasma | IL-1β | IL-10 | IL-6 | NF-κB | TNF-α | 2-AG | CELLS | IL-1 | 2-ARACHIDONYL GLYCEROL | NF-B | RECEPTOR | NECROSIS-FACTOR-ALPHA | TNF | ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL | COX-2 EXPRESSION | IN-VIVO | PHARMACOLOGY & PHARMACY | NF-KAPPA-B | CANNABINOIDS | Benzodioxoles - antagonists & inhibitors | Spleen - immunology | Frontal Lobe - metabolism | Male | Spleen - drug effects | Prostaglandins - blood | Lipopolysaccharides | Monoacylglycerol Lipases - metabolism | Arachidonic Acids - metabolism | Glycerides - blood | Arachidonic Acids - blood | Enzyme Inhibitors - chemistry | Anti-Anxiety Agents - therapeutic use | Benzodioxoles - therapeutic use | Peritonitis - metabolism | Rats | Encephalitis - immunology | Random Allocation | Glycerides - metabolism | Enzyme Inhibitors - therapeutic use | Rats, Sprague-Dawley | Cannabinoid Receptor Antagonists - therapeutic use | Monoacylglycerol Lipases - blood | Peritonitis - drug therapy | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Endocannabinoids - metabolism | Nerve Tissue Proteins - blood | Monoacylglycerol Lipases - antagonists & inhibitors | Piperidines - antagonists & inhibitors | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors | Encephalitis - drug therapy | Encephalitis - metabolism | Cytokines - blood | Nerve Tissue Proteins - antagonists & inhibitors | Cytokines - metabolism | Peritonitis - immunology | Nerve Tissue Proteins - metabolism | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Spleen - metabolism | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Frontal Lobe - drug effects | Cannabinoid Receptor Antagonists - chemistry | Frontal Lobe - immunology | Cytokines - antagonists & inhibitors | Endocannabinoids - blood | Prostaglandins - metabolism | Glycerin | Brain | Unsaturated fatty acids | Cytokines | Glycerol | Lipase | Mitogens | Plasma | Rodents | Cannabinoids 2012, Part Two | Themed Section
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 02/2014, Volume 348, Issue 2, pp. 316 - 323
The cannabinoid system has been demonstrated to modulate the acute and chronic pain of multiple origins. Mouse VD-hemopressin (alpha) [(m)VD-Hp alpha], an... 
CB1 | PAIN | MODELS | ENDOCANNABINOID SYSTEM | RATS | PHARMACOLOGY & PHARMACY | MICE | MECHANISMS | BLOCKADE | ANALGESIA | Central Nervous System - metabolism | Male | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | Cannabinoid Receptor Agonists - chemistry | Oligopeptides - adverse effects | Oligopeptides - therapeutic use | Hemoglobins - administration & dosage | Hemoglobins - adverse effects | Receptor, Cannabinoid, CB1 - agonists | Cannabinoid Receptor Agonists - adverse effects | Cannabinoid Receptor Agonists - therapeutic use | Cannabinoid Receptor Antagonists - pharmacology | Behavior, Animal - drug effects | Body Temperature Regulation - drug effects | Neurons - metabolism | Neurons - drug effects | Oligopeptides - chemistry | Hemoglobins - therapeutic use | Analgesics - adverse effects | Receptors, Opioid - metabolism | Injections, Spinal | Analgesics - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Nerve Tissue Proteins - agonists | Peptide Fragments - administration & dosage | Analgesics - administration & dosage | Appetite Regulation - drug effects | Cannabinoid Receptor Antagonists - adverse effects | Mice, Inbred Strains | Cannabinoid Receptor Agonists - administration & dosage | Nerve Tissue Proteins - metabolism | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Hemoglobins - chemistry | Peptide Fragments - chemistry | Animals | Analgesics - antagonists & inhibitors | Narcotic Antagonists - pharmacology | Central Nervous System - drug effects | Mice | Oligopeptides - administration & dosage | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Infusions, Intraventricular
Journal Article
Journal Article
Journal Article